Safety of Subchronic Treatment with Fluoxetine for Major Depressive Disorder in Children and Adolescents

Nilsson, Mary; Joliat, Melissa J.; Miner, C.; Brown, Eileen; Heiligenstein, John H.

doi:10.1089/1044546042389136

Cited by 4 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of other trial phases have been previously reported (Emslie et al 2002;Emslie et al 2004;Nilsson et al 2004;Emslie et al 2005). During the acute treatment phase of this trial, a fixed dosing regimen of fluoxetine 20 mg/day was associated with significantly greater improvement in depressive symptoms than placebo; the effect size for improvement on the CDRS-R was 0.51.…”

Section: Introduction M Ajor Depressive Disorder (Mdd) In Childrenmentioning

confidence: 52%

See 1 more Smart Citation

Fluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot Study

Heiligenstein¹,

Hoog²,

Wagner

et al. 2006

Journal of Child and Adolescent Psychopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introduction M Ajor Depressive Disorder (Mdd) In Childrenmentioning

confidence: 52%

“…Efficacy measures reported in this paper are the CDRS-R, a clinician-rated instrument that measures the presence and severity of depression in children (Poznanski et al 1985); the CGISeverity scale (NIMH 1976); and the CGI-Improvement scale (NIMH 1976).…”

Section: Efficacy and Safety Measuresmentioning

confidence: 99%

Fluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot Study

Heiligenstein¹,

Hoog²,

Wagner

et al. 2006

Journal of Child and Adolescent Psychopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…These studies are summarized, reviewed, and discussed. Several other studies with instructive findings were also identified Nilsson et al 2004;Wagner et al OCD 2004;The Paediatric OCD Treatment Study team, 2004); these are briefly considered.…”

Section: Resultsmentioning

confidence: 90%

“…Nilsson et al (2004) found that, after just 19 weeks of treatment, subjects (aged 9Á17 years) receiving fluoxetine (10 Á60 mg/day) gained an average of 1.1 cm less in height, and 1.1 kg less in weight, than placebo-treated patients. It is not clear whether the growth retardation was directly due to the drug or secondary to decreased appetite.…”

Section: The Use Of Ssris In Paediatric Subjects: Other Unfavourable mentioning

confidence: 98%

“…Whereas one subject receiving fluoxetine dropped out due to treatment-emergent agitation, incident suicidal ideation and behaviour did not differ between the groups (n 0/1, each). Nilsson et al (2004) examined the safety of subchronic treatment with fluoxetine (10 Á60 mg/ day; n 0/ 49) or placebo (n 0/ 47) in children and adolescents with major depressive disorder. After up to 19 weeks of treatment, there was no difference in the rate of reported suicide-related events between fluoxetine and placebo.…”

Section: Recent Forensic Datamentioning

confidence: 99%

See 1 more Smart Citation

Controversy revisited: selective serotonin reuptake inhibitors in paediatric depression

Andrade¹,

Bhakta²,

Singh³

2006

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

Psychotherapeutic interventions may not always be feasible or effective, especially when depression is more severe. The failure to prescribe a drug may, at the very least, lead to the loss of the placebo effect. It is therefore suggested that, if the diagnosis of unipolar depression is confident, appropriate doses of fluoxetine may be prescribed to depressed children and adolescents; the use of rescue medication to treat emergent agitation is important, and augmentation with psychotherapy may further improve outcomes. The monitoring of indices of growth may also be necessary.

show abstract

The effect of antidepressants and antipsychotics on weight gain in children and adolescents

et al. 2015

View full text Add to dashboard Cite

Psychiatric illness in the paediatric population is increasing and the weight effect of medications for these problems is often unclear. A comprehensive literature search was undertaken to identify studies reporting weight in relation to antipsychotic and antidepressant use in children and adolescents. From 636 articles, 42 were selected for review. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) do not cause weight gain and may lead to improvements in weight status over the short, but not, long term. Antipsychotics were generally associated with weight gain. In drug comparison studies, risperidone had a larger weight gain effect than lithium, divalproex sodium and pimozide. Studies assessing the weight-protective effects of augmentation therapy with metformin or topiramate show less weight gain with addition of these agents. In conclusion, prescribing of SSRIs and SNRIs may be associated with improvements in weight status in children and adolescents but trials assessing their use in obesity, outside of established psychiatric illness, are limited and still experimental. Youth prescribed antipsychotic medication should be monitored for exaggerated weight gain and in those where obesity is a pre-existing concern agents other than olanzapine, clozapine and risperidone may be advantageous.

show abstract

Safety of Subchronic Treatment with Fluoxetine for Major Depressive Disorder in Children and Adolescents

Cited by 4 publications

References 0 publications

Fluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot Study

Fluoxetine 40–60 mg versus Fluoxetine 20 mg in the Treatment of Children and Adolescents with a Less-Than-Complete Response to Nine-Week Treatment with Fluoxetine 10–20 mg: APilot Study

Controversy revisited: selective serotonin reuptake inhibitors in paediatric depression

The effect of antidepressants and antipsychotics on weight gain in children and adolescents

Contact Info

Product

Resources

About